Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Siemens Molecular Imaging
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Normal Volunteers
Subject may be male or female and of any race / ethnicity
Subject is \> 18 years old at the time of investigational product administration
Subject or subject's legally acceptable representative provides written informed consent
Subject is capable of complying with study procedures
Subject is capable of communicating with study personnel
Cancer Subjects
Subject may be male or female and of any race / ethnicity
Subject is \> 18 years old at the time of investigational product administration
Subject or subject's legally acceptable representative provides written informed consent
Subject is capable of complying with study procedures
Subject is capable of communicating with study personnel
Subject must have histologically confirmed stage III, or IV squamous cell carcinoma of the head and neck whose primary origin was from the oral cavity, oropharynx, hypopharynx, or larynx. Carcinoma must be staged using the American Joint Committee on Cancer (AJCC) staging criteria version 6. Adequate tumor must be amenable to biopsy via outpatient methods
According to the Karnofsky Performance Status Scale, the subject has a value of ≥ 60% at time of screening
Subject is scheduled for a clinical FDG PET scan either within 48 hours prior to (with no intervention in between the two scans), or within 48 hours after the investigational \[F-18\]HX4 PET scan
Subject must have normal organ and renal function as defined:
* total bilirubin within normal institutional limits
* AST(SGOT)/ALT(SGPT) less than or equal to 2.5 x institutional upper limit of normal
* creatinine within normal institutional limits
* BUN within normal institutional limits
You may not be if
Normal Volunteers
Subject is younger than 18 years old at the time of investigational product administration
Female subject is pregnant or nursing--Serum pregnancy test must be negative; test must be completed within 24 hours of dosing or female subject must be either surgically sterilized or post- menopausal, defined as at least one year without menses as reported by the subject
Subject is unable to remain still for duration of imaging procedure (\~40 mins)
Subject has previously received \[F-18\]HX4 at any time, or has been involved in an investigative, radioactive research procedure within the past year
Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data
Subject has a history of significant prescription or non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives.
Cancer Subjects
Subject is younger than 18 years old at the time of investigational product administration
Female subject is pregnant or has a positive serum pregnancy test
Subject is unable to remain still for duration of imaging procedure
Subject has a history of significant renal disease
Subject has previously received \[F-18\]HX4 at any time, or any other investigational product in the past thirty days.
Subject has been involved in an investigative, radioactive research procedure within the past year
Inadequate tumor sites or volume to allow for biopsy
Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete and good quality data
Subject has a history of significant prescription or non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives